Advertisement

Introduction of a Simple Second Tier Screening Test for C5 Isobars in Dried Blood Spots: Reducing the False Positive Rate for Isovaleric Acidaemia in Expanded Newborn Screening

  • R. S. CarlingEmail author
  • D. Burden
  • I. Hutton
  • R. Randle
  • K. John
  • J. R. Bonham
Research Report
Part of the JIMD Reports book series (JIMD, volume 38)

Abstract

In 2015 the English Newborn Screening programme expanded to include Isovaleric Acidaemia (IVA). Screening is performed by flow injection analysis tandem mass spectrometry of isovalerylcarnitine. Isovalerylcarnitine is isobaric with pivaloylcarnitine which can be present in blood due to the use of pivalic ester pro-drugs or pivalic acid derivatives used as emollients in some nipple creams; the potential for false positives (FP) is well documented. A pilot study in England screened 438,164 babies, 18 had presumptive positive results but only 4 were confirmed as true positives (TP). We developed a simple test to separate the isobaric compounds and investigate these samples further.

We studied newborn screening blood spots from 122 randomised controls and 34 infants with an initial raised C5 result. Dried blood spots were eluted with 30% acetonitrile (150 μL) and injected into a Waters Acquity UPLC coupled to a Waters Premier XE tandem mass spectrometer operating in positive ion mode. Isocratic separation of isovalerylcarnitine, pivaloylcarnitine, valerylcarnitine and 2-methylbutyrylcarnitine was achieved within 8 min. Assay performance characteristics were acceptable and non-parametric reference ranges (n = 122) were determined for each analyte.

If this method had been used as a second tier test for the 34 presumptive positive samples, the number of FP’s would have reduced from 24 to 8 and the positive predictive value of the screening test would have increased from 29 to 56%. Introduction of this test into the screening protocol has the potential to significantly reduce FP results for IVA and prevent unnecessary anxiety.

References

  1. Abdenur JE, Chamoles NA, Guinle AE et al (1998) False positive result due to pivaloylcarnitine in a newborn screening programme. J Inherit Metab Dis 21:624–630CrossRefPubMedGoogle Scholar
  2. Boemer F, Schoos R, de Halleux V et al (2014) Surprising causes of C5-carnitine false positive results in newborn screening. Mol Gen Metab 111:52–54CrossRefGoogle Scholar
  3. Bonham JR (2013) Impact of new screening technologies: should we screen and does phenotype influence this decision? J Inherit Metab Dis 36:681–686CrossRefPubMedGoogle Scholar
  4. Dewar S, Reed L, Koerner R (2014) Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother 69(2):303–308CrossRefPubMedGoogle Scholar
  5. Ensenauer R, Vockley J, Willard JM et al (2004) A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet 75:1136–1142CrossRefPubMedPubMedCentralGoogle Scholar
  6. Moorthie S, Cameron L, Sagoo G, Burton H (2013) Birth prevalence of five inherited metabolic diseases. A systematic review. PHG FoundationGoogle Scholar
  7. Powell-Smith A, Goldacre B (2015) OpenPrescribing.Net
  8. Public Health England (2016) Management of infection guidance for primary care for consultation and local adaptationGoogle Scholar
  9. Tanaka K (1990) Isovaleric academia: personal history, clinical survey and study of molecular basis. Prog Clin Biol Res 321:273–290PubMedGoogle Scholar
  10. Vockley J, Parimoo B, Nagao M, Tanaka K (1992) Identification of the molecular defects responsible for the various genotypes of isovaleric acidemia. Prog Clin Biol Res 375:533–540PubMedGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • R. S. Carling
    • 1
    Email author
  • D. Burden
    • 1
  • I. Hutton
    • 1
  • R. Randle
    • 1
  • K. John
    • 1
  • J. R. Bonham
    • 2
  1. 1.South East Thames Regional Newborn Screening Laboratory, Biochemical SciencesViapath, Guys & St Thomas’ NHSFTLondonUK
  2. 2.Division of Pharmacy, Diagnostics and GeneticsSheffield Children’s (NHS) FTSheffieldUK

Personalised recommendations